Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2293 : ACC-MESO-4  update : 2021/02/26
CommentHuman malignant pleural mesothelioma cell line.
Comment from the depositor
Terms and conditionsIn publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Cancer Sci 2006;97:387-394) designated by the DEPOSITOR is required.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Sekido, Yoshitaka
Originator Hida, Toyoaki
Year of deposit 2006
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 59 years
Tissue malignant pleural mesothelioma, pleural fluid
Disease name malignant pleural mesothelioma
Classification cancer
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin or (0.05% trypsin + 0.53mM EDTA) or (0.25% trypsin + 0.53mM EDTA)
Culture information Passage ratio 1 : 6 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 1
User's Publication 32


To topTop
Reference
3337  Usami, Noriyasu, Fukui, Takayuki, Kondo, Masashi, Taniguchi, Tetsuo, Yokoyama, Toshihiko, Mori, Shoichi, Yokoi, Kohei, Horio, Yoshitsugu, Shimokata, Kaoru, Sekido, Yoshitaka, Hida, Toyoaki  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.  Cancer Sci  2006  97:387-94  PubMed ID: 16630136

To topTop
User's Publication
20093  Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng RW, Yao F.  NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.  Cancers (Basel)  2021  13(7)  PubMed ID: 33805359
6938  Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E.  Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition.  Mol Cancer Ther  2020  19(2):552-563  PubMed ID: 31619462
12125  Fujii T, Itami H, Uchiyama T, Morita K, Nakai T, Hatakeyama K, Sugimoto A, Shimada K, Tsuji S, Ohbayashi C.  HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.  Biochem. Biophys. Res. Commun.  2020    PubMed ID: 32284171
13129  Kojima M, Kajino K, Momose S, Wali N, Hlaing MT, Han B, Yue L, Abe M, Fujii T, Ikeda K, Hino O.  Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.  Respir Res  2020    PubMed ID: 32677949
13171  Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, Peng RW.  Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.  Cancers (Basel)  2020    PubMed ID: 32824422
13236  Jotatsu T, Izumi H, Morimoto Y, Yatera K.  Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis.  Oncol Rep  2020    PubMed ID: 33000251
13275  Sakai K, Nishiuchi T, Tange S, Suzuki Y, Yano S, Terashima M, Suzuki T, Matsumoto K.  Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion.  Sci Rep  2020    PubMed ID: 33028834
13551  Han B, Lee-Okada HC, Ishimine M, Orita H, Nishikawa K, Takagaki T, Kajino K, Yokomizo T, Hino O, Kobayashi T.  Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells  FEBS Open Bio  2020  10(11):2375-2387  PubMed ID: 32961616
13608  Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y, Tanaka F.  Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2  Cells  2020  9(4):888  PubMed ID: 32260559
11413  Nakayama K, Seike M, Noro R, Takeuchi S, Matsuda K, Kunugi S, Kubota K, Gemma A.  Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.  Anticancer Res.  2019    PubMed ID: 30711938
11837  Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW.  Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.  Cancers (Basel)  2019    PubMed ID: 31597321
12382  Yoneda K, Kuwata T, Chikaishi Y, Mori M, Kanayama M, Takenaka M, Oka S, Hirai A, Imanishi N, Kuroda K, Ichiki Y, Ohnaga T, Tanaka F.  Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma  Cancer Sci  2019  110(2):726-733  PubMed ID: 30499156
12383  Hino O, Abe M, Han B, Yan Y.  In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma  Cancer Sci  2019  110(5):1518-1524  PubMed ID: 30888083
10679  Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.  Capture of mesothelioma cells with 'universal' CTC-chip.  Oncol Lett  2018  15:2635-2640  PubMed ID: 29434985
11150  Ohno Y, Shingyoku S, Miyake S, Tanaka A, Fudesaka S, Shimizu Y, Yoshifuji A, Yamawaki Y, Yoshida S, Tanaka S, Sakura K, Tanaka T.  Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.  Oncogene  2018  37(49):6357-6367  PubMed ID: 30061637
11107  Xu D, Liang SQ, Yang H, Luthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW.  Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.  Br. J. Cancer  2018  119(1):65-75  PubMed ID: 29921948
11217  Matsuura R, Kaji H, Tomioka A, Sato T, Narimatsu H, Moriwaki Y, Misawa H, Imai K, Tsuji S.  Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.  Sci Rep  2018    PubMed ID: 30250045
7034  Tsuji S, Washimi K, Kageyama T, Yamashita M, Yoshihara M, Matsuura R, Yokose T, Kameda Y, Hayashi H, Morohoshi T, Tsuura Y, Yusa T, Sato T, Togayachi A, Narimatsu H, Nagasaki T, Nakamoto K, Moriwaki Y, Misawa H, Hiroshima K, Miyagi Y, Imai K.  HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.  Sci Rep  2017  7:45768  PubMed ID: 28361969
10043  Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.  Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.  Lung Cancer  2017  104:98-105  PubMed ID: 28213009
10329  Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E.  Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.  Front Genet  2017  8:70  PubMed ID: 28611824
10639  Shigeeda W, Shibazaki M, Yasuhira S, Masuda T, Tanita T, Kaneko Y, Sato T, Sekido Y, Maesawa C.  Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.  Oncotarget  2017  8:93729-93740  PubMed ID: 29212185
9731  Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.  Establishment of anti-mesothelioma monoclonal antibodies.  BMC Res Notes  2016  9:324  PubMed ID: 27342200
5814  Lourdes Cortes-Dericks, Laurene Froment, Gregor Kocher, Author information Article notes Copyright and License infor  Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines  Stem Cell Res Ther  2016  7:25  PubMed ID: 26861734
10036  Jelena Kresoja-Rakic, Esra Kapaklikaya, Gabriela Ziltener, Damian Dalcher, Raffaella Santoro, Brock C Christensen, Kevin C Johnson, Beat Schwaller, Walter Weder, Rolf A Stahel, Emanuela Felley-Bosco  Identification of Cis- And Trans-Acting Elements Regulating Calretinin Expression in Mesothelioma Cells  Oncotarget  2016  7(16):21272-86  PubMed ID: 26848772
12632  Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y.  Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma  Int J Oncol  2016  48(4):1599-607  PubMed ID: 26820394
12680  Kushitani K, Amatya VJ, Mawas AS, Miyata Y, Okada M, Takeshima Y.  Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia  Pathobiology  2016  83(1):33-40  PubMed ID: 26735863
13697  Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G.  Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity  BMC Cancer  2014  14:304  PubMed ID: 24884875
8088  Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.  Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.  Int. J. Cancer  2011  129:1005-17  PubMed ID: 20949562
8199  Hasegawa S, Koshikawa-Yano M, Saito S, Morokoshi Y, Furukawa T, Aoki I, Saga T.  Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.  Int. J. Cancer  2011  128:2138-46  PubMed ID: 20617513
8186  Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.  Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.  Br. J. Cancer  2010  103:517-23  PubMed ID: 20628387
8379  Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K.  Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.  Int. J. Cancer  2010  127:1948-57  PubMed ID: 20104519
13735  Ito A, Hagiyama M, Mimura T, Matsumoto M, Wakayama T, Iseki S, Yokozaki H, Okada M.  Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium  Lab Invest  2008  88(5):504-14  PubMed ID: 18332875



Back Back Return Top Page